PaperTumour necrosis factor increases tumour uptake of Co-administered antibody-carboxypeptidase G2 conjugate
References (24)
- et al.
Antineoplastic glucuronide prodrug treatment of human tumour cells targeted with a monoclonal antibody enzyme conjugate
Biochem Pharmacol
(1991) - et al.
A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody beta-lactamase conjugate for the treatment of cancer
Bioorg Medicinal Chem Letter
(1991) - et al.
Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2
J Immunol Meth
(1993) - et al.
Construction and chemotherapeutic potential of carboxypeptidase A/monoclonal antibody conjugate
Adv Enzyme Regul
(1991) - et al.
A cytotoxic agent can be generated selectively at cancer sites
Br J Cancer
(1988) - et al.
Anti-tumour effects of antibody-alkaline phosphatase conjugates in combinaton with etoposide phosphate
- et al.
Antibody directed enzyme prodrug therapy (ADEPT)—Clinical Report
Disease Markers
(1991) - et al.
Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates
Cancer Res
(1989) - et al.
In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate
Bioconjugate Chem
(1991) - et al.
Antibody-penicillin-V-amidase conjugates kill antigen-positive tumour cells when combined with doxorubicin phenoxyacetamide
Cancer Immunol Immunother
(1991)
Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions
J Immunol
(1983)
Definition of antigenic heterogeneity and modulation among human mammary carcinoma cell populations using monoclonal antibodies to tumour-associated antigens
Cancer Res
(1983)
Cited by (0)
Copyright © 1993 Published by Elsevier Ltd.